Literature DB >> 22234687

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.

Shaji Kumar1, Rafael Fonseca, Rhett P Ketterling, Angela Dispenzieri, Martha Q Lacy, Morie A Gertz, Suzanne R Hayman, Francis K Buadi, David Dingli, Ryan A Knudson, Alexandra Greenberg, Stephen J Russell, Steven R Zeldenrust, John A Lust, Robert A Kyle, Leif Bergsagel, S Vincent Rajkumar.   

Abstract

Routine incorporation of FISH into multiple myeloma (MM) diagnostic testing has led to a better appreciation of the heterogeneity of genetic abnormalities associated with this disease. We studied a group of 484 patients with newly diagnosed symptomatic MM to better understand the prevalence of the various abnormalities and the prognostic significance of the overlapping abnormalities. A translocation involving the IgH locus and 1 of the 5 recurrent partner chromosomes was seen in 161 (33%) patients, and 275 (57%) had trisomy of at least 1 odd-numbered chromosome. High-risk FISH, defined as the presence of t(4;14), t(14;16), t(14;20), or loss of P53, was seen in 115 (24%) patients; the median overall survival for this group was 3.9 years, compared with "not reached" for standard-risk patients (P < .001). Among the patients with high-risk FISH, 49 patients who also had at least 1 trisomy had a median overall survival that was not reached, compared with 3 years for high-risk patients without a concurrent trisomy (P = .01). Based on the current findings, we conclude that the presence of trisomies in patients with t(4;14), t(14;16), t(14;20), or p53 deletion abnormalities in MM ameliorates the usual adverse impact associated with these prognostic markers.

Entities:  

Mesh:

Year:  2012        PMID: 22234687      PMCID: PMC3311247          DOI: 10.1182/blood-2011-11-390658

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

Authors:  Hervé Avet-Loiseau; Xavier Leleu; Murielle Roussel; Philippe Moreau; Catherine Guerin-Charbonnel; Denis Caillot; Gérald Marit; Lotfi Benboubker; Laurent Voillat; Claire Mathiot; Brigitte Kolb; Margaret Macro; Loïc Campion; Marc Wetterwald; Anne-Marie Stoppa; Cyrille Hulin; Thierry Facon; Michel Attal; Stéphane Minvielle; Jean-Luc Harousseau
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

2.  Do beta2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy?

Authors:  W J Chng; S Jacobus; R Fonseca
Journal:  Leukemia       Date:  2007-11-29       Impact factor: 11.528

3.  Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.

Authors:  Shaji K Kumar; Hajime Uno; Susanna J Jacobus; Scott A Van Wier; Greg J Ahmann; Kimberly J Henderson; Natalie S Callander; Jessica L Haug; David S Siegel; Philip R Greipp; Rafael Fonseca; S Vincent Rajkumar
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

4.  Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.

Authors:  T Facon; H Avet-Loiseau; G Guillerm; P Moreau; F Geneviève; M Zandecki; J L Laï; X Leleu; J P Jouet; F Bauters; J L Harousseau; R Bataille; J Y Mary
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

5.  Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.

Authors:  Prashant Kapoor; Rafael Fonseca; S Vincent Rajkumar; Shirshendu Sinha; Morie A Gertz; A Keith Stewart; P Leif Bergsagel; Martha Q Lacy; David D Dingli; Rhett P Ketterling; Francis Buadi; Robert A Kyle; Thomas E Witzig; Philip R Greipp; Angela Dispenzieri; Shaji Kumar
Journal:  Mayo Clin Proc       Date:  2010-06       Impact factor: 7.616

6.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Authors:  Shaji K Kumar; Joseph R Mikhael; Francis K Buadi; David Dingli; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Philip R Greipp; Suzanne R Hayman; Robert A Kyle; Martha Q Lacy; John A Lust; Craig B Reeder; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; P Leif Bergsagel
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

7.  Clinical and biologic implications of recurrent genomic aberrations in myeloma.

Authors:  Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

Review 8.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

9.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors:  Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

10.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

View more
  93 in total

1.  Haematological cancer: Lenalidomide maintenance--perils of a premature denouement.

Authors:  S Vincent Rajkumar
Journal:  Nat Rev Clin Oncol       Date:  2012-06-05       Impact factor: 66.675

2.  Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.

Authors:  S K Kumar; E Ma; A E Engebretson; F K Buadi; M Q Lacy; A Dispenzieri; M S Duh; M-H Lafeuille; P Lefebvre; W Y Cheng; K Dea; D Rembert; D Patt; L Niculescu; M Quick; S V Rajkumar
Journal:  Leukemia       Date:  2015-08-14       Impact factor: 11.528

3.  Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.

Authors:  Alexandra J Greenberg; Denise K Walters; Shaji K Kumar; S Vincent Rajkumar; Diane F Jelinek
Journal:  Eur J Haematol       Date:  2013-09-17       Impact factor: 2.997

Review 4.  A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?

Authors:  Damian J Green; William I Bensinger
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 5.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

6.  Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

Authors: 
Journal:  Am J Hematol       Date:  2018-08-16       Impact factor: 10.047

7.  Natural history of t(11;14) multiple myeloma.

Authors:  A Lakshman; M Alhaj Moustafa; S V Rajkumar; A Dispenzieri; M A Gertz; F K Buadi; M Q Lacy; D Dingli; A L Fonder; S R Hayman; M A Hobbs; W I Gonsalves; Y L Hwa; P Kapoor; N Leung; R S Go; Y Lin; T V Kourelis; J A Lust; S J Russell; S R Zeldenrust; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2017-06-27       Impact factor: 11.528

Review 8.  Current Review on High-Risk Multiple Myeloma.

Authors:  Henry S H Chan; Christine I Chen; Donna E Reece
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 3.952

Review 9.  Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Int J Hematol       Date:  2013-02-28       Impact factor: 2.490

10.  [Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis].

Authors:  S C Brandelik; J Krzykalla; T Hielscher; J Hillengass; J K Kloth; H U Kauczor; M A Weber
Journal:  Radiologe       Date:  2018-01       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.